Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.

Exclusion Criteria

• •1. Within the past 3 months prior to the screening period, there has been a history of peritonitis, other infections, or inflammatory diseases, with hospitalization records;
• •2. The possibility of receiving a kidney transplant during the study period;
• •3. Patients with inadequate dialysis and screening period kt/v\<1.4;
• •4. Patients with hemoglobin less than 80g/L during the screening period;
• •5. Patients who have used amino acid (15) peritoneal dialysate within 6 months prior to the screening period.
• •6. Patients with bleeding events (active gastrointestinal hemorrhage, cerebral hemorrhage), cardiovascular and cerebrovascular events (cerebral infarction, myocardial infarction, etc., and NYHA grade ≥3 of cardiac function) within 30 days before screening period.
• •7. In patients with active diarrhea during the screening period, as assessed by investigators, affecting nutrient absorption(Except for patients with chronic diarrhea, stool frequency \< 3 times/day);
• •8. patients with contraindications to amino acid (15) peritoneal dialysis solutions: 1) hypersensitivity to any of the components of the product; 2) Serum urea level \>38 mmol/l; 3) Presence of uremic symptoms such as marked loss of appetite, nausea and vomiting at the time of screening; 4) Various inborn abnormalities of amino acid metabolism; 5) hepatic insufficiency (active hepatitis); active hepatitis B or C, cirrhosis, active liver disease or positive seropositivity for human immunodeficiency virus (HIV) within 6 months prior to screening; 6) Uncorrectable mechanical defects that the investigator assesses as affecting efficacy or increasing the risk of infection; 7) History of loss of peritoneal function or impairment of peritoneal function due to extensive adhesions;
• •9. Suffers from a malignant tumor or has a life expectancy of \&lt;6 months;
• •10. Routine daily use of 4.25% glucose dialysis solution during the screening period;
• •11. Diabetic subjects with poor prior glycemic control, e.g., HbAlc \> 8%;
• •12. Women during pregnancy or breastfeeding;
• •13. Other circumstances that, in the opinion of the investigator, may make participation in this study inappropriate.